Presented at #EULAR2026:
In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: https://t.co/Lynf6nmA9N
Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease https://t.co/BUQ7r8jVWz
@eular_org
We've written about AI-induced physician deskilling that has already surfaced
https://t.co/iMy6zyWnhZ @tberzin
AI-induced never-skilling among newly trained doctors, while not yet proven, is a serious concern that needs to be addressed @NatureMedicine@nliulab
https://t.co/yov3YvsGti
Off-label Use of Nemolizumab to Address Pruritic Skin Disease: A Case Series in DM Patients
✨Rapid improvement in refractory pruritus and cutaneous disease activity in a case series of 5 dermatomyositis patients.
No serious adverse events observed. 📖
https://t.co/YT4mxSn76x
"Guidelines should help clinicians and patients make better decisions, but too often they do the opposite."
Overcoming ambiguous guideline recommendations
https://t.co/n1aMdDR2FI
🔬 Real-world study
Isolated Anti-SSB vs combined Anti-SSA and Anti-SSB
315 patients
Found isolated anti-SSB + was associated with ⬇️ rates of Sjögren disease, SLE, RA, xerophthalmia, and autoantibody positivity compared with combined anti-SSA/SSB abs
https://t.co/u8crzBuOTn
FDA has approved benralizumab (Fasenra) for the treatment of adult and pediatric patients w/ hypereosinophilic syndrome (HES); based on the NATRON Phase III trial https://t.co/qqPsjhUClP
Changing patterns in hospitalisations of patients with # SLE over three decades at a tertiary referral centre in Catalonia. https://t.co/qhBSqBOmxR #ScholarAlerts